Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jef­frey Kindler’s plan to take his biotech — which is de­vel­op­ing a slate of non-opi­oid painkillers — pub­lic, is back on.

The Boston based com­pa­ny, led by for­mer Pfiz­er $PFE chief Kindler, orig­i­nal­ly con­tem­plat­ed a $70 mil­lion to $80 mil­lion IPO last year— but even­tu­al­ly post­poned that strat­e­gy. On Wednes­day, the com­pa­ny re­vived its bid to make a pub­lic de­but in a fil­ing with the SEC — al­though no pric­ing de­tails were dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER